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One of the greatest national security threats to the United States is the detonation of an improvised
nuclear device or a radiological dispersal device in a heavily populated area. As such, this type of secu-
rity threat is considered to be of relatively low risk, but one that would have an extraordinary high
impact on health and well-being of the US citizenry. Psychological counseling and medical assessments
would be necessary for all those signiﬁcantly impacted by the nuclear/radiological event. Direct med-
ical interventions would be necessary for all those individuals who had received substantial radiation
exposures (e.g., >1 Gy). Although no drugs or products have yet been speciﬁcally approved by the
United States Food and Drug Administration (US FDA) to treat the effects of acute radiation syndrome
(ARS), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating fac-
tor (GM-CSF), and pegylated G-CSF have been used off label for treating radiation accident victims.
Recent threats of terrorist attacks using nuclear or radiologic devices makes it imperative that the med-
ical community have up-to-date information and a clear understanding of treatment protocols using
therapeutically effective recombinant growth factors and cytokines such as G-CSF and GM-CSF for
patients exposed to injurious doses of ionizing radiation. Based on limited human studies with under-
lying biology, we see that the recombinants, G-CSF and GM-CSF appear to have modest, but signiﬁcant
medicinal value in treating radiation accident victims. In the near future, the US FDA may approve
G-CSF and GM-CSF as ‘Emergency Use Authorization’ (EUA) for managing radiation-induced aplasia,
an ARS-related pathology. In this article, we review the status of growth factors for the treatment of
radiological/nuclear accident victims.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction
Acute radiation syndrome (ARS) occurs in humans following
whole-body or signiﬁcant partial-body exposures to ionizing radi-
ation with doses greater than 1 Gy, delivered at relatively high
rates. Clinical components of ARS include the hematopoietic sub-
syndrome (H-ARS, 2–6 Gy), gastrointestinal sub-syndrome (GIS;
6–8 Gy), and the cerebrovascular (>8 Gy) sub-syndrome [1].
However, these ‘‘sub-syndromes’’ tend to oversimplify the clinical
reality of ARS as it often involves complex, multi-organ dysfunc-
tions [2–4]. The cerebrovascular sub-syndrome is consideredincurable, whereas, individuals receiving lower radiation doses
that result in either the H-ARS alone or in combination with GIS,
are more likely to be amenable to countermeasures. Therefore,
the latter two sub-syndromes are speciﬁc targets for the develop-
ment of novel therapeutics. This is particularly the case in terms of
H-ARS, that is largely driven by the radiation-induced loss of vital,
growth factor-modulated hematopoietic progenitors and, in turn,
by massive losses of circulating, functions blood cells, i.e., the blood
cytopenias.
Colony-stimulating factors are endogenous glycoproteins that
induce bone marrow hematopoietic progenitors to proliferate
and differentiate into speciﬁc mature blood cell types [5,6].
Granulocyte colony-stimulating factor (G-CSF) is a lineage speciﬁc
colony-stimulating factor produced by monocytes, ﬁbroblasts, and
endothelial cells. It regulates the production of neutrophils within
the bone marrow and affects neutrophil progenitor proliferation
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phagocytic ability [10], respiratory burst [11], antibody-mediated
killing [12], and the increased expression of cell surface antigens
[13]. G-CSF is not species-speciﬁc and several, biologically similar
analogs of G-CSF have been reported (Biograstim/Filgrastim
ratiopharm/Ratiograstim/Tevagrastim (XM02); Zarzio and Niv-
estim) [14]. It acts by binding to a G-CSF speciﬁc transmembrane
receptor (belonging to the class I cytokine receptor family), which
are expressed on various hematopoietic cells such as stem cells,
multi-potential progenitors, myeloid-committed progenitors, neu-
trophils, and monocytes. The receptor forms homo-oligomeric
complexes upon ligand binding. Its mode of action and role in dif-
ferentiation/maturation of cells are graphically represented in
Fig. 1. It has been approved for the following clinical indications:
(a) cancer patients receiving myelosuppressive chemotherapy, (b)
patients with acute myeloid leukemia receiving induction or con-
solidation chemotherapy, (c) cancer patients receiving bone mar-
row transplants (BMT), (d) patients undergoing peripheral blood
progenitor cell collection and therapy, (e) patients with severe
chronic neutropenia.
Tbo-ﬁlgrastim (a short-acting recombinant non-glycosylated,
bio-similar form of G-CSF, Tevagrastim: Teva Pharmaceutical
Industries Ltd., Israel/Sicor Biotech UAB, Vilnius, Lithuania, also
known as XM02) was granted United States Food and Drug
Administration (US FDA) approval on 29 August 2012 to help
reduce the duration of severe neutropenia in patients with non-
myeloid malignancies receiving myelosuppressive anti-cancer
drugs associated with clinically signiﬁcant incidence of febrile
neutropenia [15]. Although both tbo-ﬁlgrastim and ﬁlgrastim
(Neupogen, Amgen Inc., Thousand Oaks, CA, USA) have a struc-
ture containing 175 amino acids and are produced through
recombinant DNA technology in the Escherichia coli bacteria, they
have different formulations [16]. The sponsor for tbo-ﬁlgrastim,
Teva Pharmaceuticals, rather than following the abbreviated
pathway for bio-similar compounds and relying on clinical efﬁ-
cacy and safety data for ﬁlgrastim, submitted a full biological
licensing application (BLA) with clinical efﬁcacy and safety data
obtained from studies with tbo-ﬁlgrastim to the FDA for approval
(the abbreviated pathway was not available with the US FDA at
the time of submission). The indication, for which tbo-ﬁlgrastim
was approved, is narrower than those for ﬁlgrastim based on
the clinical data included in the biological licensing application.
The US FDA does not consider tbo-ﬁlgrastim to be bio-similar to
or interchangeable with ﬁlgrastim [15].
Another US FDA-approved product is pegﬁlgrastim (pegylated
G-CSF: Neulasta, Amgen Inc.), a sustained-duration form of
ﬁlgrastim. It consists of the ﬁlgrastim molecule with a 20 kDa
monomethoxypolyethylene glycol molecule covalently bound to
the N-terminal methionyl residue for an average molecular weight
of approximately 39 kDa [17]. The biological activity and mecha-
nism of action of the pegylated and non-pegylated forms are iden-
tical so clinical requirements determine which form will be used
[18]. Pegﬁlgrastim, administered to cancer patients undergoing
treatment, is typically injected once, 24 h after each cycle of
high-dose chemotherapy and no sooner than 14 days before the
next chemo treatment. Filgrastim is typically injected on a daily
basis until neutrophil counts come back to normal levels.
GM-CSF, like G-CSF, is a hematopoietic growth factor that
stimulates proliferation and differentiation of hematopoietic pro-
genitor cells. GM-CSF can activate mature granulocytes and mac-
rophages and is able to induce partially committed progenitor
cells in the granulocyte–macrophage pathways to divide and dif-
ferentiate. Functional cells later in this differentiation pathway
include neutrophils, monocytes/macrophages and myeloid-
derived dendritic cells. Additionally, GM-CSF is a bi-lineage factor
able to affect the myelomonocytic lineage in a dose-dependentmanner and can promote the proliferation of not only progenitors
committed to granulocyte and monocyte production, but also a
limited capacity to stimulate megakaryocytic and erythroid pro-
genitors as well, although other factors are required to induce
complete maturation of the latter two lineages [19]. The spe-
cies-speciﬁc biological activity and various cellular responses
(i.e., division, maturation, activation) are induced through GM-
CSF binding to speciﬁc receptors expressed on the cell surface
of target cells [20]. It has been approved for use, by the US
FDA, for the following clinical indications: (a) neutrophil recovery
following chemotherapy in acute myelogenous leukemia, (b)
mobilization of peripheral blood progenitor cells, (c) post periph-
eral blood progenitor cell transplantation, (d) myeloid reconstitu-
tion after autologous or allogeneic BMT, (e) BMT failure or
engraftment delay.
Currently, there are four recombinant leukocyte growth factors
with BLA approval: BLA 103353, Neupogen (ﬁlgrastim, Amgen,
Inc.), BLA 125031, Neulasta (pegﬁlgrastim, Amgen, Inc.), BLA
103362, Leukine (sargramostim, Genzyme Inc., Cambridge, MA,
USA) and BLA 125294, TBO-Filgrastim (tbo-ﬁlgrastim, Sicor Bio-
tech, UAB) [21]. The use of growth factors in treating victims in a
radiation-exposure scenario is rationalized based on the following
three facts: (a) improved survival in irradiated animals (mice,
canines, minipigs, and NHPs), (b) improved neutrophil recovery
in cancer patients-treated with growth factors, and (c) an observed
diminished period of neutropenia in a limited number of radiation
accident victims treated with ﬁlgrastim and sargramostim [22].
The limited clinical data available regarding these growth factors
validate their biological response. However, the problem with this
limited data is the manner in which these recombinants have been
administered; in almost all cases, administration was delayed,
under varying conditions, making the CSF’s role in recovery difﬁ-
cult to determine deﬁnitively.
The US emergency use authorization (EUA) is a critical new tool
for the medical and public health communities. It is applicable for
both civilian and military use, as it ﬁlls the need for timely and
practical medical treatment in emergency situations. The Project
BioShield Act of 2004, among other provisions, established the
comprehensive EUA program. EUA permits the US FDA to approve
the emergency off-label use of products approved for other indica-
tions or the use of drugs, devices, and medical products holding no
prior approval, clearance, or licensing by FDA. Prior to the estab-
lishment of the EUA, the sole mechanism for making unapproved
products available in an emergency situation, was through obtain-
ing Investigational New Drug (IND) status.
On the 3rd of May, 2013, the US FDA Center for Drug Evalua-
tion and Research convened a joint meeting of the Medical Imag-
ing Drugs Advisory Committee and the Oncologic Drug Advisory
Committee to discuss the safety and efﬁcacy of currently
approved leucocyte growth factors as potential treatments for
radiation-induced myelosuppression associated with a radiologi-
cal/nuclear incident. During this meeting the committee consid-
ered the known ﬁlgrastim effects in the chemotherapy setting,
as well as comparable ﬁlgrastim effects in severely myelosup-
pressed humans exposed acutely to ionizing radiation following
a radiological/nuclear incident. Members voted in overwhelming
support (17:1) of the concept that recombinant human G-CSF
(rhG-CSF) would likely to produce signiﬁcant clinical beneﬁt in
humans exposed unwantedly to radiation as a consequence of a
given radiation accident [23].
In light of the above mentioned US FDA meeting and related
events, we have tried here in this brief review to elaborate on
recent preclinical and clinical developments associated with these
leukocyte growth factors and to provide the information available
on their therapeutic use and potentials in medically managing the
hematopoietic component of ARS.
Fig. 1. Binding, signal transduction and role of G-CSF in hematopoietic cell maturation/differentiation. G-CSF binds to its transmembrane receptor (G-CSFR), and initiates a
signaling cascade by phosphorylating/activating Janus kinase 2 (JAK-2). The activated JAK-2 can then initiate many signaling pathways, three of which are described here in
abbreviated form. Each portrayed pathway is involved in stimulating cell proliferation, cell differentiation or the inhibition of apoptosis, indicated by the pink, green and blue
colored signals, respectively. Green arrows indicate stimulation and red arrows indicate inhibition. Self-replacing hematopoietic cells give rise to multi-potent stem cells,
which in turn give rise to lymphoid progenitors, erythroid progenitors, megakaryocytes, basophil progenitors, eosinophil progenitors or granulocyte–monocyte progenitors.
Erythroid, megakaryocyte, basophil, eosinophil progenitors give rise to erythrocytes, platelets, basophils and eosinophils, respectively. Granulocyte–monocyte progenitors
give rise to neutrophils and monocytes by stimulation with G-CSF with additional cytokines and growth factors such as IL-3, GM-CSF, and M-CSF. (STAT – signal transducer
and activator of transcription, STAT5 – transcription factor of 5B, STAT3 – transcription factor of 3, P indicates phosphorylated or activated signal, RAS – Rat Sarcoma,
RAF – rapid accelerated ﬁbrosarcoma – extracellular-signal-regulated kinase 5, P13K – phosphatidylinositol-4,5-bisphosphate 3-kinase (phophatidylinositide 3-kinases), BAD
– Bcl-2 associated death promoter, BCLxL – B-cell lymphoma-extra-large, CASPASES – cysteine-aspartic proteases AKA cysteine-dependent aspartate-directed proteases, PDK
– pyruvate dehydrogenase kinase, AKT – protein kinase B, a serine/threonine-speciﬁc protein kinase, BcL-2 – an anti-apoptotic protein, CiAP2 – Baculoviral IAP repeat-
containing protein 3).
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production
In the recent past, we have demonstrated that high levels of
G-CSF are induced in mice by the administration of several
promising radiation countermeasures that are currently under
development. These new countermeasures include agents such as5-androstenediol (5-AED/Neumune) [24,25], CBLB502 (truncated
ﬂagellin: Entolimod™) [26], CBLB612 and CBLB613 (both lipopep-
tides of mycoplasma origin) [27,28], vitamin E isomers and their
derivatives (d-tocotrienol [29,30], c-tocotrienol [31], and a-tocoph-
erol succinate [32,33]). Further, we have demonstrated in mice, that
the administration of a G-CSF antibody completely abrogates the
radioprotective efﬁcacy of some radiation countermeasures (e.g.,
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and a-tocopherol succinate [33,35]), clearly suggesting that
G-CSF, plays an important role in the radioprotective efﬁcacy of
these countermeasures. Recently, G-CSF and interleukin-6 (IL-6)
have been identiﬁed as candidate biomarkers for the radioprotec-
tive and radiomitigative efﬁcacy of CBLB502. Induction of both
G-CSF and IL-6 by CBLB502 is toll-like receptor 5-dependent,
dose-dependent within its efﬁcacious dose range in both unirradi-
ated and irradiated mammals (including rodents, canines, and
NHPs), with both factors deemed critically important for CBLB502’s
efﬁcacy in increasing the survival of acutely irradiated animals
[26]. These biomarkers may be useful for accurately predicting
the dose of CBLB502 required to provide sufﬁcient levels of radio-
protection or radiomitigation in radiation-injured humans.
Other investigators also have reported stimulation of G-CSF by
potential radiation countermeasures in mice. Meloxicam (a selec-
tive inhibitor of cyclooxygenase-2) protected mice against c-radi-
ation exposure and stimulated high levels of G-CSF when
administered intraperitoneally (ip) [36–39]. Bar-Yehuda et al. have
demonstrated stimulation of G-CSF by oral administration of
CF101 (a myeloprotective synthetic agonist to the A3 adenosine
receptor) by upregulation of phosphoinositide 3-kinase/nuclear
factor-jB in mice [40]. Maitake beta-glucan (MD-fraction, polysac-
charide derived from Grifola frondosa) stimulated G-CSF in granul-
ocytopenic mice when administered ip, and subsequently,
enhanced both granulopoiesis and the mobilization of granulo-
cytes and their progenitors [41].
In acutely irradiated mice, maximal peripheral blood levels of
G-CSF occur approximately 8 h after radiation exposure [42–44].
A second peak of G-CSF occurs around 12 days after 9.2 Gy radia-
tion exposure (60Co) in CD2F1 mice [42]. Administration of a
G-CSF antibody neutralizes radiation-induced G-CSF and signiﬁ-
cantly enhanced mortality in irradiated mice [43]. Interestingly,
comparable administrations of the G-CSF antibody to acutely irra-
diated mice also increase the cell lethality in intestinal tissues (i.e.,
as reﬂected by the increased number of apoptotic cells within
intestinal villi). In aggregate, these experimental observations
clearly indicate that: (a) acute and intense radiation exposures
induce markedly elevated levels of circulating G-CSF; (b) the
administration of a G-CSF neutralizing antibody exacerbates the
deleterious effects of radiation; and (c) G-CSF induction in response
to radiation exposure may be playing an important role in recovery.3. Additive or synergistic effects of combining G-CSF with other
drugs
Several agents have been used in combination with G-CSF to
enhance its efﬁcacy in various experimental models. However,
the possible future use of such therapeutic drug combinations,
regardless of effectiveness in treating ARS, may be limited and
restricted by the lack of speciﬁc EUAs by the US-FDA for such drug
combinations. Nevertheless and despite the regulatory hurdles, it
seems reasonable to suggest that a number of these drug combina-
tions might prove effective in enhancing the therapeutic potential
of recombinant G-CSF in the clinical management of ARS.
A combination of dipyridamole (cellular adenosine uptake
inhibitor) and adenosine monophosphate (an adenosine prodrug)
exhibited radioprotective efﬁcacy by enhancing hematopoiesis
[45]. Combining dipyridamole and adenosine monophosphate
enhanced the efﬁcacy of G-CSF [46]. Because the combination of
G-CSF, dipyridamole and adenosine monophosphate enhanced
endogenous spleen colony formation in irradiated mice, it was
interesting to test whether interaction with extracellular adeno-
sine and G-CSF also occurs at the level of the hematopoietic pro-
genitors generating these colonies. Dipyridamole and adenosinemonophosphate acted additively with G-CSF to enhance spleen
colony formation [47]. These ﬁndings indicate that the signaling
pathways of G-CSF and drugs elevating extracellular adenosine
can interact at the level of multipotential hematopoietic progeni-
tors. Enhancement of the hematopoiesis-stimulating effects of
G-CSF by dipyridamole and adenosine monophosphate, which are
low-priced and clinically available drugs, may improve the cost-
effectiveness of G-CSF therapy.
One study demonstrated that therapeutically administered
G-CSF accelerates hematopoietic reconstitution from amifostine-
protected stem and progenitor cells, increasing the survival-
enhancing effects of amifostine [48]. In this study, female C3H/
HeN mice were administered amifostine (200 mg/kg, ip, 30 min
before 60Co irradiation) to protect hematopoietic stem cells and
G-CSF (125 lg/kg/day, subcutaneously (sc), from day 1 to 16 after
irradiation) to stimulate proliferation and reconstitution of the
hematopoietic system. This study again reinforces that concept
that classic radioprotectants and recombinant hematopoietic
growth factors can be used in combination to reduce risks associ-
ated with myelosuppression induced by radiation or by radiomi-
metic drugs. The dose reduction factor (DRF) obtained for the
amifostine/G-CSF combination-treated mice (1.64) exceeded the
DRF of G-CSF-treated mice (1.06) and amifostine-treated mice
(1.44). Additionally, bone marrow, splenic multipotential hemato-
poietic progenitors granulocyte/macrophage-committed progeni-
tors, peripheral white blood cell, platelet, and red blood cell
recoveries were accelerated in mice treated with the combination
of amifostine and G-CSF. This study was repeated using different
doses of the two agents and conﬁrmed their earlier ﬁndings [49].
There are several similar reports demonstrating the additive and
synergistic effects of G-CSF in combination with synthokine
SC-55494 (synthetic IL-3 receptor agonist), glucan (macrophage
activator), mast cell growth factor (c-kit ligand), and IL-6 in mouse
and NHP models for survival or improvement of myelosuppression
(neutropenia/thrombocytopenia) [50–55].
There is an additional report demonstrating the beneﬁcial
effects of combining IL-3 and GM-CSF in NHP exposed to 4.5 Gy
of mixed ﬁssion neutron: c-radiation [56]. The combined treat-
ment consisted of IL-3 and GM-CSF each administered (sc), two
times a day, with doses of 12.5 lg/kg. IL-3 was administered on
day 1–7 and GM-CSF on days 7–21. These combined administra-
tions reduced the average 16 days period of neutropenia with anti-
biotic support in the control animals to 6 days in the treated group.
Similarly, the average 10 days period of severe thrombocytopenia,
which necessitated transfusions of platelets in the control animals,
was reduced to 3 days. There was no improved granulocyte pro-
duction between the combined administration of IL-3 plus GM-
CSF and GM-CSF alone. Also, the combination treatment was less
effective than IL-3 alone in reducing thrombocytopenia. Granulo-
cyte function was enhanced in all cytokine-treated animals. We
are currently experimenting with a similar combination of amifos-
tine and other radiation countermeasures that induce high levels of
G-CSF.4. Commercially available G-CSF/GM-CSF
Various preparations of G-CSF, pegylated G-CSF, and GM-CSF
currently available for clinical use are discussed in the sections
below. A summary of these sections has been presented in Table 1.4.1. Neupogen
This product is the Amgen Inc. trademark for ﬁlgrastim, which
has been selected as the name for recombinant methionyl human
G-CSF (r-metHuG-CSF). As stated above, Neupogen (Amgen,
Table 1
Various preparations of G-CSF, pegylated G-CSF, and GM-CSF available for clinical use.
Product Manufacturer Product details Indications Administration schedule References
Neupogen/ﬁlgrastim Amgen, Inc.,
Thousand
Oaks, CA, USA
Recombinant methionyl
human G-CSF from E. coli
expression system, liquid form
 Cancer patients receiving myelosuppressive
chemotherapy
 Following bone marrow transplant
5 or 10 lg/kg/day, sc, or
iv, short or continuous
infusion, different
schedules used in
different studies
[57]
Tevagrastim/Tbo-ﬁlgrastim Sicor Biotech
UAB, Vilnius,
Lithuania
Alternate form of G-CSF
developed after Neupogen
patent expiration, liquid form
 Reduces neutropenia in patients receiving
myelosuppressive anti-cancer drugs
5 lg/kg/day, sc injection
until neutrophil nadir has
passed
[16]
Neulasta/Pegﬁlgrastim/
pegG-CSF
Amgen, Inc.,
Thousand
Oaks, CA, USA
Pegylated form of ﬁlgrastim
incorporating
monomethoxypolyethylene
glycol molecule, liquid form
 Decreases incidents of infection manifested
by febrile neutropenia in patients receiving
anti-cancer medications associated with
clinically signiﬁcant incidence of febrile
neutropenia
Single 6 mg sc injection
per chemotherapy cycle,
long acting agent
[17,18]
Leukine/Sargramostim Sanoﬁ-
Aventis US
LLC,
Bridgewater,
NJ, USA
Recombinant human GM-CSF
using yeast (Saccharomyces
cerevisiae) expression system,
liquid and powder forms
 Neutrophil recovery following chemother-
apy for acute myeologenous leukemia
 Post peripheral blood progenitor cell
transplantation
250 lg/m2/day, iv,
administered with
different schedules in
different studies
[58]
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recombinant DNA technology using the E. coli K802 bacteria
expression system [57]. Though, the protein has an amino acid
sequence that is identical to the natural sequence predicted from
the analysis of human DNA, it has an addition of N-terminal methi-
onine, necessary for expression in E. coli. Furthermore, it is non-
glycosylated also due to being produced by E. coli expression. Thus,
Neupogen differs from G-CSF isolated from a human cell (or any
mammalian cells).
For cancer patients receiving myelosuppressive chemotherapy,
the starting dose of Neupogen is 5 lg/kg/day, administered as a
single daily injection by sc bolus injection, short intravenous (iv)
infusion (15–30 min) or by continuous sc or iv infusion. Neupo-
gen should be administered daily for up to 2 weeks until the
patient’s neutrophil count has reached 10,000/ll following the
expected chemotherapy-induced neutrophil nadir. The recom-
mended dose of Neupogen following BMT is 10 lg/kg/day given
as an iv infusion at 4 or 24 h, or as a continuous 24 h sc infusion.
Neupogen is not recommended to patients with known hypersen-
sitivity to E. coli-derived proteins, ﬁlgrastim, or any component of
the product.
4.2. Tevagrastim/Tbo-ﬁlgrastim
As stated above, Tbo-ﬁlgrastim (Sicor Biotech UAB, distributed
by: Teva Pharmaceuticals USA, North Wales, PA) is another form
of G-CSF, developed following the expiration of the Neupogen
patent. Tbo-ﬁlgrastim was approved, with narrower indications
than those for Neupogen, to reduce the duration of severe neutro-
penia in patients with non-myeloid malignancies receiving myelo-
suppressive anti-cancer drugs that are associated with a clinically
signiﬁcant incidence of febrile neutropenia. The recommended
dose of Tbo-ﬁlgrastim is 5 lg/kg/day administered as a sc injection.
Daily dosing with Tbo-ﬁlgrastim should continue until the
expected neutrophil nadir is passed and the neutrophil count has
recovered to the normal range [16].
4.3. Neulasta
Neulasta (PEGﬁlgrastim; Amgen, Inc.) is a covalent conjugate
of recombinant methionyl human G-CSF (ﬁlgrastim) and mono-
methoxypolyethylene glycol. Neulasta is indicated to decrease
the incidence of infection, as manifested by febrile neutropenia,in patients with non-myeloid malignancies receiving myelosup-
pressive anti-cancer drugs associated with a clinically signiﬁcant
incidence of febrile neutropenia [17,18]. Unlike Neupogen, Neul-
asta is not indicated for mobilizing peripheral blood progenitor
cells for hematopoietic stem cell transplantation. The recom-
mended dosage of Neulasta is a single sc injection of 6 mg admin-
istered once per chemotherapy cycle.
4.4. Leukine/(sargramostim)
Leukine (Sanoﬁ-Aventis U.S. LLC, Bridgewater, NJ, USA) is a
recombinant human GM-CSF (rhGM-CSF) produced by recombi-
nant DNA technology using the Saccharomyces cerevisiae (yeast)
expression system. Leukine is a glycoprotein consisting of 127
amino acids, characterized by three primary molecular species,
having molecular weights of 19,500, 16,800 and 15,500 Da. The
amino acid sequence of Leukine differs from the natural human
GM-CSF by a substitution of leucine at position 23, and the carbo-
hydrate moiety may be different from the native protein. Sargram-
ostim was selected as the proper name for yeast-derived rhGM-
CSF.
For neutrophil recovery following chemotherapy for acute mye-
logenous leukemia, the recommended dose of Leukine is 250 lg/
m2/day administered iv over a 4 h period starting approximately
on day 4 or 11 following the completion of induction chemother-
apy. The recommended dose for post-peripheral blood progenitor
cell transplantation is 250 lg/m2/day administered iv over a 2-h
period beginning 2–4 h after bone marrow infusion, and no less
than 24 h after the last dose of chemotherapy or radiotherapy
(details obtained from product sheet) [58].
5. Stockpile of G-CSF to treat ARS
The Centers for Disease Control’s Strategic National Stockpile
(SNS) is a national repository of antibiotics, chemical antidotes,
antitoxins, life-support medications, iv administration items, air-
way maintenance supplies, and medical/surgical items. The SNS
is designed to supplement and re-supply state and local public
health agencies in the event of a national emergency anywhere
and anytime within the US or its territories [59]. The US Depart-
ment of Health and Human Services (HHS) will transfer authority
for the SNS material to the state and local authorities once it
arrives at the designated receiving and storage site. The SNS is
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within the immediate response 12-h Push Packages. These are
caches of pharmaceuticals, antidotes, and medical supplies
designed to provide rapid delivery of a broad spectrum of agents
for an ill-deﬁned threat in the early hours of an event. These Push
Packages are positioned in strategically located, secure warehouses
ready for immediate deployment to a designated site within 12 h
of the federal decision to deploy SNS assets. The SNS program
ensures that the medical material stock is rotated and kept within
potency shelf-life limits [22,60,61].
The HHS Ofﬁce of the Assistant Secretary for Preparedness and
Response Biomedical Advanced Research and Development
Authority, Project BioShield is the chief mechanism through which
the US government supports the advanced development and pro-
curement of new medical countermeasures—drugs, vaccines, diag-
nostics, and medical supplies—to protect the health of US citizens
against chemical, biological, radiological and nuclear threats.
Under the Project BioShield Act of 2004, the Biomedical Advanced
Research and Development Authority has supported the develop-
ment and procurement of medical countermeasures, drugs and
products to treat illnesses ranging from anthrax, smallpox, and
botulism to the impacts of ionizing radiation.
As previously stated, G-CSF and GM-CSF are approved by the US
FDA for cancer patients undergoing chemotherapy to speed white
blood cell recovery and reduce the risk of infection. In 2013, HHS
awarded a $157.5 million contract to Amgen USA Inc., to purchase
Neupogen (Filgrastim: G-CSF) [62]. The leukocyte growth factors
acquired under this contract will remain in the possession of the
manufacturers in vendor-managed inventory until they are
needed. The companies will rotate this inventory to meet commer-
cial demand so the inventory does not expire. This was the ﬁrst
time under Project BioShield that commercially available products
were purchased to establish a sustainable emergency response
capability. HHS also awarded a $36.5 million contract to Sanoﬁ-
Aventis for late-stage development and procurement of Leukine
(Sargramostim: GM-CSF).
Although G-CSF has not been approved by the FDA for treating
ARS victims, it has been procured (along with GM-CSF) to be stock-
piled in the SNS under the Pandemic and All-Hazards Preparedness
Reauthorization Act (PAHPRA) of 2013. PAHPRA signiﬁcantly
expands FDA authority to support medical countermeasure pre-
paredness and response efforts for chemical, biological, radiologi-
cal, or nuclear (CBRN) emergencies [63]. PAHPRA clariﬁes part of
the FDA’s authority to issue EUA, which allows use of unapproved
medical products or unapproved uses of approved products leading
up to or during an emergency in the absence of adequate,
approved, and available alternatives. There are instances when
the FDA issues EUAs ahead of a declared emergency; these
instances include when HHS determines that there is signiﬁcant
potential for an emergency involving a CBRN agent that affects or
has signiﬁcant potential to affect national security or the health
and security of US citizens abroad. Governmental pre-preposition-
ing permits federal, state, and local governments to pre-position
medical countermeasures in anticipation of approval or clearance,
or issuance of a EUA to enable them to better prepare for potential
rapid deployment during an actual CBRN emergency.6. Preclinical efﬁcacy of G-CSF and GM-CSF across various
species
Preclinical studies in mouse, canine, mini-pig, and NHP models
demonstrate reduced severity of myelosuppression with enhanced
neutrophil recovery and improved survival after G-CSF or GM-CSF
treatments when exposed to lethal or sub-lethal doses of radiation
(Table 2). We focus our discussion below on the effects on survivaland on the recovery of blood leukocytes (neutrophils) conducted in
different animal models. In a majority of studies, survival and
blood response proﬁles were primary efﬁcacy endpoints. We have
divided this section into G-CSF and GM-CSF to better organize all
studies conducted with these CSF.
6.1. Studies with G-CSF
The radioprotective efﬁcacy of G-CSF has been evaluated in dif-
ferent strains of mice, canines (beagle), and NHP, with one recent
report of using G-CSF therapeutically in the minipig [64]. A major-
ity of these studies have used recombinant G-CSF of human origin
because G-CSF is not species-speciﬁc. Most of the investigators
have used Amgen’s recombinant G-CSF (Neupogen/ﬁlgrastim)
but a few have used G-CSF from other sources. The results of multi-
ple studies suggest that G-CSF consistently enhanced survival and
the recovery of blood leukocytes (neutrophils) across various spe-
cies (mice, beagle, minipig, and NHP) regardless of radiation source
(c-ray, X-ray, mixed ﬁeld—neutron and gamma). The demon-
strated radioprotective efﬁcacy of G-CSF was dependent on drug
dose, the drug treatment schedule in relation to radiation expo-
sure, duration of the treatment and the dose of radiation. The esti-
mated DRFs for G-CSF were 1.06 [48], 1.1 [65] or 1.2 [66],
depending on G-CSF dose, treatment schedule, route of administra-
tion, and strains of mice [67]. The rhG-CSF increased the number of
blood-circulating neutrophils, monocytes and erythrocytes, but not
that of lymphocytes and thrombocytes.
Various treatment schedules were reported as well: for exam-
ple, rhG-CSF administered twice (1 lg/dose, twice daily, ip, day
0–6) protected BDF1 mice against 8.5 Gy X-ray (0.6 Gy/min) TBI
[68]. Another study reported that rhG-CSF (100 lg/kg/day, sc start-
ing 1 h after radiation exposure for the next 3 days (Neutrogin,
Choongwae, Seoul, Korea) protected C3H/HeN mice against par-
tial-body irradiation (12 Gy, 3.8 Gy/min, abdominal exposure)
[69]. G-CSF also protected C3H/HeN female mice when adminis-
tered 2.5 lg/day, sc, on days 3–12 following 8 Gy total body irradi-
ation (TBI) [53]. In a mouse survival assay, G-CSF (0.34 mg/kg, sc,
12, 24, and 48 h after irradiation) also was effective as a post-irra-
diation mitigator against injuries stemming from both c-photons
(8.0–9.0 Gy and mixed-ﬁeld irradiation (8.0, 8.5 and 9.0 Gy c-rays
and 4.63, 4.92, and 5.21 Gy mixed ﬁeld, respectively) [70]. In a
recent study it has been observed that G-CSF appears to protect
both irradiated and combined injury (irradiated and wounded)
mice. G-CSF has not been tested in a murine combined injury
model of irradiation and burn [71].
Contrary to the above positive ﬁndings of therapeutic effective-
ness of these recombinants, there is one report in a mouse model
where the use of G-CSF did not show a survival beneﬁt [72]. This
study administered a single ip dose of G-CSF (up to 2 lg/mouse)
one or 3 h after 8 Gy (LD95/30) 60Co TBI. This study did show how-
ever, that recombinant GM-CSF also failed to show efﬁcacy but
recombinant human IL-1, recombinant murine interferon-c, and
recombinant human tumor necrosis factor were effective. In addi-
tion, reports suggest variable responses of G-CSF in different
strains of mice, and the optimal dose of G-CSF also varies in differ-
ent strains [73,74]. In these studies, however, G-CSF was adminis-
tered very shortly following irradiation and not therapeutically to
irradiated animals.
The estimated DRFs for acutely irradiated canines (beagles)
given therapeutic doses of recombinant G-CSF (10 lg/kg/day, sc,
daily for 21 days starting on day 1 post-TBI) and with or without
full supportive care were 1.73 and 1.34, respectively [75]. The sup-
portive care regimen consisted of infusions of ﬂuids, antibiotics,
and fresh irradiated platelets. In another study, eight out of ten
canines receiving G-CSF (Amgen; 10 lg/kg/day, sc, twice a day
for 21 day) survived with complete and sustained hematopoietic
Table 2
Details of G-CSF/GM-CSF use in animal models of ARS for efﬁcacy.
Product Animal
model
Treatment and radiation details Treatment outcome References
G-CSF/ﬁlgrastim/
Neupogen
Mice 125 lg/kg/day, sc, day 1–16 post-irradiation DRF 1.06 [48]
2.25 lg/mouse, ip, twice a day, days 1–14 post-irradiation DRF 1.2 [66]
1 mg/kg, 2 h after irradiation DRF 1.1 [65]
Various doses and schedules in different strains of mice Radiomitigation against c-rays and X-rays
observed
[48,53,65,68]
0.34 mg/kg, sc, 12, 24, and 48 h post-irradiation, (8.0, 8.5 and
9.0 Gy c-rays, 4.63, 4.92, and 5.21 Gy neutron for mixed ﬁeld,
respectively)
Treatment protected mice against c-rays and
mixed ﬁeld (gamma-rays and neutron)
[70]
2 lg/mouse, ip, 1 or 3 h after 8 Gy (LD95/30) 60Co c-irradiation No radiomitigative efﬁcacy observed [72]
100 lg/kg/day, sc starting 1 h post-irradiation for 3 days –
(Neutrogin, Choongwae, Seoul, Korea), 12 Gy abdominal
exposure
Treatment protected C3H/HeN mice against
partial-body irradiation
[69]
Various doses and routes (sc/ip) used against different doses
of radiation in different strains of mice
Treatment demonstrated efﬁcacy of G-CSF when
administered before radiation exposure
[73,74]
Beagle
canine
10 lg/kg/day, sc, 1–21 days post-irradiation DRF 1.73 (without supportive care), 1.34
(with supportive care)
[75]
10 lg/kg/day, sc, twice a day for 21 days, 2–4 Gy Treatment improved survival and sustained
hematopoietic recovery
[76–79]
10 lg/kg/day, sc, once a day starting within 1 h of irradiation
and continued for 21 days after 2.3 Gy mixed ﬁssion-neutron-
gamma irradiation (Hangzhou Jiuyuan Gene Engineering Co.,
Hangzhou, China)
Treatment improved survival, leukopenia, and
neutropenia compared to control
[80]
Minipigs 10 lg/kg/day for 17 d, sc, starting 24 h (±1 h) post-irradiation,
1.78 Gy
Treatment enhanced survival and stimulated
recovery from neutropenia
[64]
NHP 10 lg/kg/day, sc, beginning 1 day after 7.5 Gy TBI until the
absolute neutrophil count > 1,000/ll for 3 consecutive days.
All NHPs received medical management/supportive care
Treatment effectively mitigated the lethality of
the hematopoietic ARS, reduced 60 day mortality,
decreased the duration of neutropenia
[81]
Pegylated G-CSF/
PEGﬁlgrastim/
Neulasta
Mice 100 lg/kg, 24 ± 4 h post 8.7 Gy 137Cs TBI Treatment demonstrated protective efﬁcacy in
C57BL/6 male/female mice
[89]
NHP 300 lg/kg, on day 1 or days 1 and 7 post-irradiation, 6 Gy Administration at days 1 and 7 was most effective
at improving neutrophil recovery after severe,
radiation-induced myelosuppression
[82]
GM-CSF/
(sargramostim)/
Leukine
Mice 10 Gy 60Co TBI, followed by allogeneic transplantation the
following day, 200 ng/mouse, ip, twice a day, starting the day
following transplant for 14 days
Treatment enhanced survival and neutrophil
recovery
[91]
Canine 50 lg/kg, twice a day for 21 days starting on day 1 after 4
GyTBI
Treatment shifted the LD50/60 from 3.8 Gy to 4.5 Gy [75]
50 lg/kg, twice daily for 5 doses and then continued at 25 lg/kg
twice daily for 21 days or until death, 4 Gy
Treatment was not effective in promoting
hematopoietic recovery or improving survival
[76]
NHP 72,000 U/kg/day for 7 days post-lethal, non-uniform radiation
exposure of 8 Gy
Treatment demonstrated improved granulocyte
and platelet levels 4 and 7 days earlier,
respectively, than control, early recovery of
GM-CFU
[92]
Studies conducted with G-CSF or GM-CSF in combination with other cytokines in various animal models have not been included in above table.
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after TBI for the ﬁrst 18 days in the G-CSF group and the neutrophil
nadirs were higher. In yet another study, data indicated that G-CSF
treatment could increase survival in irradiated canine through the
induction of earlier recovery of neutrophils and platelets [77].
There are additional studies demonstrating neutrophil recovery
by both rhG-CSF and recombinant canine G-CSF in irradiated
canines [78,79].
Fission-neutron radiation damage is generally difﬁcult to treat
due to the combined nature and repair of injuries to both the
hematopoietic and GI systems. However, in at least one study,
the therapeutic effect of rhG-CSF (Hangzhou Jiuyuan Gene Engi-
neering Co., Hangzhou, China) was clearly demonstrated. In this
study, dogs received 2.3 Gy, whole-body, mixed ﬁssion-neutron-
gamma irradiation with a high ratio of neutrons (90%) [80]. Fol-
lowing irradiation, rhG-CSF treatments were administered
(10 lg/kg/day, sc, once a day starting within 1 h of irradiation
and continued for 21 days), resulting in 100% survival of the trea-
ted group vs 60% survival in control group. Only two of ﬁve rhG-
CSF-treated dogs experienced leukopenia (white blood cell,
WBC < 1.0  109/L) and neutropenia (neutrophil < 0.5  109/L),
whereas all irradiated controls displayed a profound period of leu-
kopenia and neutropenia. Furthermore, administration of rhG-CSFsigniﬁcantly delayed the onset of leukopenia and reduced the
duration of leukopenia as compared with controls. Thus, these
results demonstrated that rhG-CSF administration enhanced
recovery of myelopoiesis and survival after ﬁssion neutron-
irradiation.
Clinically beneﬁcial effects of recombinant G-CSF treatments
have been reported recently for acutely gamma irradiated
(LD70/30 TBI, 1.78 Gy) minipigs (male Gottingen minipigs,
4–5 months of age). A post-exposure treatment regimen consisting
of rhG-CSF at 10 lg/kg/day for 17 d, sc, starting 24 h after TBI,
resulted in enhanced survival and stimulated recovery from
neutropenia [64]. However, additional studies will be needed to
judge the suitability of this animal model for studying radiation
countermeasures.
An extended, carefully conducted study in NHPs (Macaca mul-
atta, Chinese substrain) of rhG-CSF’s (ﬁlgrastim) efﬁcacy has
clearly demonstrated a survival beneﬁt associated with such
treatments. In this study, a cohort of 46 randomized animals,
24 ﬁlgrastim-treated (20 male and 4 female) and 22 control (18
male and 4 female)) was exposed to an LD50/60 dose (7.5 Gy, an
approximate mid-lethal dose, 0.8 Gy/min) of 6 MV linear acceler-
ator-derived photon radiation. Filgrastim (10 lg/kg/day, sc) was
administered, beginning 1 day after irradiation and continued
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secutive days. All NHPs received medical management/supportive
care [81]. Overall, the primary end point was survival at 60 days
post-irradiation. Secondary end points included mean survival
time of decedents and other hematologic parameters. Again, as
indicated earlier, ﬁlgrastim effectively mitigated the lethality
stemming from the hematopoietic component of ARS. Speciﬁcally,
ﬁlgrastim signiﬁcantly reduced 60 day overall mortality (20.8% (5/
24)) compared to controls (59.1% (13/22)). Filgrastim also
decreased the duration of neutropenia but did not affect the abso-
lute neutrophil count nadir. Survival signiﬁcantly increased com-
pared to controls.
G-CSF generally enhanced hematopoietic recovery in all animal
species and strains studied [48,51,64,67,68,76–80,82–87]. The
beneﬁcial effects of G-CSF were measured as decreased duration
of neutropenia, decreased time for neutrophil recovery, improved
neutrophil nadir, increased WBC count, and increased granulo-
cyte/macrophage colony-forming units (GM-CFU) in bone marrow.
As a consequence of such observations that support the concept
that recombinant G-CSF treatments provide substantial therapeu-
tic beneﬁt, the Centers for Disease Control and Prevention cur-
rently has an IND Application (with the US FDA) containing a
detail clinical protocol for how G-CSF/ﬁlgrastim would be adminis-
tered to exposed victims in the event of a radiological nuclear inci-
dent [23].6.2. Studies with pegylated G-CSF
Modiﬁcation of proteins with polyethylene glycol (PEG) results
in increased size which reduces renal clearance and prolongs half-
life, thereby reducing the need for daily dosing. One such amended
recombinant growth factor, Neulasta (pegylated human G-CSF,
Amgen, Inc.), has demonstrated efﬁcacy of neutrophil recovery
enhancement in animals and humans with drug- or radiation-
induced neutropenia, utilizing only one or two doses. The pegylat-
ed G-CSF molecule has more potent hematopoietic properties than
corresponding non-pegylated G-CSF [88]. Neulasta (as well as
Maxy-G34) has been bioengineered to contain 5 amino acid substi-
tutions of the native G-CSF and three polyethylene glycol conjuga-
tion at unique site and has been demonstrated protective efﬁcacy
in C57BL/6 male/female mice against 8.7 Gy (137Cs) when adminis-
tered as a single sc dose (100 lg/kg) at 24 ± 4 h post-TBI [89]. The
‘one low dose administration’ schedule is an attractive attribute of
a radiation countermeasure given the logistical challenges of med-
ical care in a mass-casualty scenario. Recently, it has been demon-
strated that pegylated G-CSF inhibits blood cell depletion,
surprisingly increases platelets, blocks splenomegaly, and
improves survival after whole-body ionizing irradiation but not
after irradiation combined with skin burns (15% total-body-sur-
face-area skin burns) in mice [71].
In a recent study, the efﬁcacy of PEGﬁlgrastim was evaluated in
NHPs, exposed to 6 Gy X-ray TBI (0.13 Gy/min). PEGﬁlgrastim was
administered (300 lg/kg) on day 1 or days 1 and 7 post-irradiation.
Effective plasma concentrations of PEGﬁlgrastim were maintained
in neutropenic animals until after the onset of hematopoietic
recovery. Administration of PEGﬁlgrastim at days 1 and 7 was most
effective at improving neutrophil recovery compared to daily
administration of ﬁlgrastim or a single injection of PEGﬁlgrastim
on day 1 [82]. In brief, this study demonstrated that two weekly
injections of PEGﬁlgrastim are equivalent or signiﬁcantly better
in virtually all parameters reﬂecting enhanced granulopoiesis com-
pared to 17–21 days of daily ﬁlgrastim injections. A single sc injec-
tion of pegylated ﬁlgrastim provides adequate and safe neutrophil
support, comparable to daily sc injections of ﬁlgrastim, in human
patients receiving myelosuppressive chemotherapy [90].6.3. Studies with GM-CSF
The radioprotective efﬁcacy of GM-CSF has been evaluated in
mice, canines, and NHP [75,91,92]. As stated above, unlike G-CSF,
GM-CSF has species speciﬁcity. For NHP, rhGM-CSF has been used
while both recombinant human as well as recombinant canine
GM-CSF were used in beagle canines. rhGM-CSF has no efﬁcacy
in mice and a majority of investigators have used recombinant
mouse GM-CSF, although a few used sargramostim. The survival
data of GM-CSF appear less consistent, enhancing survival in some
but not all studies. GM-CSF enhanced the neutrophil/monocyte
recovery in most of the studies. Overall, published results support
the neutrophil/monocyte fraction of the WBC recovery beneﬁt of
GM-CSF on hematopoietic ARS.
Recombinant mouse GM-CSF enhanced survival in a Balb/c
mouse allogeneic transplantation model [91]. Mice were exposed
to 10 Gy 60Co TBI followed by BMT the following day. GM-CSF
was administered ip (200 ng/mouse, twice a day) starting the
day following transplantation for 14 days. GM-CSF enhanced sur-
vival and neutrophil recovery as compared with control mice
[91].
In a study mentioned above with canines, a DRF was established
as 1.73 without supportive care and 1.34 with supportive care [75],
when rhGM-CSF was administered sc (50 lg/kg twice a day or
100 lg/kg once a day) for 21 days starting on day 1 after TBI. The
treatment with rhGM-CSF shifted the LD50/60 to 4.5 Gy from
3.8 Gy in canines receiving a full complement of supportive care.
However, the survival beneﬁt of the GM-CSF treatments in canines
was not consistently demonstrated in all studies. In another study,
the survival rate was similar between the recombinant canine GM-
CSF-treated group (1/10) and an untreated group (1/13) in a canine
model with supportive care (parenteral ﬂuids, electrolytes, platelet
transfusions, and antibiotics) [76]. In this study, canines received
4 Gy 60Co TBI and within 2 h of TBI, GM-CSF was administered sc
at a dose of 50 lg/kg twice a day for 5 doses and then continued
at 25 lg/kg twice daily for 21 days or until death. Nine canines
died between days 11–21. The causes of death were reported as
pneumonia (n = 7) or sepsis (n = 2). GM-CSF was not effective in
promoting hematopoietic recovery or improving survival. The lack
of efﬁcacy was not due to GM-CSF itself because GM-CSF (50 lg/
kg/day for 14 day, sc) increased neutrophil counts (3.0–9.3 times
the baseline) in ﬁve non-irradiated canines. In the same study,
recombinant canine G-CSF enhanced survival.
The ability of rhGM-CSF to enhance recovery of a radiation-sup-
pressed hematopoietic system was evaluated in a partial-body
radiation exposure model using rhesus NHPs [92]. rhGM-CSF treat-
ment for 7 days after a lethal, non-uniform radiation exposure of
8 Gy was sufﬁcient to enhance hematopoietic reconstitution, lead-
ing to an earlier recovery. rhGM-CSF (6.25  106 U/mg, from
Genetics Institute, Inc., Cambridge, MA) was administered iv as a
single dose of 50,000 U on either days 3 or 4 following irradiation
followed by subsequently continuous sc administration via an
implanted pump with 72,000 U/kg/day of the recombinant for 7
additional days. The two treatments partially restored circulating
blood levels of granulocytes and platelets levels, 4 and 7 days ear-
lier than control NHPs, respectively. GM-CFU activity in the bone
marrow was monitored to evaluate the effect of rhGM-CSF on
recovery of myeloid elements within bone marrow. Noting that
treatment with rhGM-CSF led to an early recovery of GM-CFU
activity, the authors suggested that rhGM-CSF might be acting on
an earlier stem cell population to generate GM-CFU.
In a majority of studies conducted in different animal models,
GM-CSF enhanced blood leukocyte recovery in various strains of
mice [52,73,83,91], beagle canines [75,93,94], and rhesus NHPs
[56,92,95] when administered alone or in combination with other
cytokines. As stated for G-CSF, the effects were assessed mainly as
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recovery, improved neutrophil nadir, increased WBC counts, and
increased GM-CFU in bone marrow.
Variations in preparation and sources of GM-CSF as well as dif-
ference in study design may contribute to the inconsistent survival
beneﬁts of GM-CSF. Results available in the published literature
support using GM-CSF to enhance blood leukocyte recovery during
the hematopoietic phase of ARS, however, the published results
of the survival beneﬁt are less convincing. There are studies where
the efﬁcacies of G-CSF and GM-CSF have been compared in
concurrent experiments in mice and canines, speciﬁcally in terms
of a survival beneﬁt: results of these comparative studies have
shown that G-CSF was found to be more effective in protecting
irradiated animals compared with GM-CSF [73,76].7. G-CSF/GM-CSF used for the treatment of radiological/nuclear
accident victims
Radioactive materials continue to be used in a variety of indus-
tries, including but not limited to energy production, construction,
medicine, and research. Concerns over adverse effects of nuclear/
radiological exposures of industrials workers and the general pop-
ulations continue. Exposure safeguards are clearly essential in
order to protect people from the detrimental effects of undue lev-
els of ionizing radiation. Where the quantity of radioactive mate-
rial is substantial, e.g. with sources used in radiotherapy or
industrial radiography, extreme care is necessary to prevent acci-
dents that may have severe consequences for the individuals
affected. In spite of all precautions, accidents with radiation
sources continue to occur, although infrequently.
Approved indications of CSF that are potentially relevant in the
treatment of ARS include use in patients with nonmyeloid malig-
nancies undergoing myeloablative chemotherapy or with subse-
quent BMT. Use of G-CSF and GM-CSF is based on the established
biologic mechanism of G-CSF/GM-CSF, which stimulate neutrophil
production, accelerate neutrophil recovery, and reduce the severity
and duration of febrile neutropenia and infections.
Although CSFs have been used with several accident victims
(Table 3), there is no randomized trial for the effectiveness of the
recombinant CSFs in patients exposed to high doses of ionizing radi-
ation; further, in such cases inwhich recombinantCSFhas beenused
therapeutically, the speciﬁc CSF product was not always identiﬁed.
Additional limitations of these case studies include the variable
radiation doses, use of growth factors other than G-CSF/GM-CSF,
large variability in the CSF dose, time of CSF administration in rela-
tion to radiation exposure, and duration of CSF administration. The
consensus guidelines recommend starting CSF as soon as possible
[22,96,97]. In some cases, CSF administration was not initiated until
weeks after the incidence [58].
There have been a larger number of accidents involving sealed
radioactive sources, such as 60C, 192Ir, or 137Cs than accidents
involving nuclear power plants, accidents in the radiation therapy
of patients, or accidents in other radiation industries [23,98]. Radi-
ation accident reports show that CSFs have been used in a wide
variety of accident situations [99,100]. Although the ﬁrst CSF was
approved by the US FDA in 1991, the ﬁrst known use of CSF was
for the Chernobyl, nuclear power plant accident in Ukraine in
1986. A year later, CSFs were used in Goiânia, Brazil, for a radiolog-
ical exposure accident involving an abandoned radiation source.
Here, we brieﬂy describe all radiation incidents since 1986, for
which CSF was used to treat the radiation exposed victims.
Although the data seem to indicate that the period of neutropenia
is shortened and survival prolonged, there is no deﬁnitive proof
that CSF administration actually decreases mortality in radiation-
exposed humans. CSF therapy is considered a valuable adjunct totreatment with antibiotics and strict hygiene controls in radia-
tion-exposed victims.
7.1. Chernobyl disaster, Soviet Union/Russia 1986
The Chernobyl disaster was a catastrophic nuclear accident that
occurred on 26 April 1986 at the Chernobyl Nuclear Power Plant in
Ukraine (then the Ukrainian SSR), which was under the Soviet
Union [101,102]. An explosion and ﬁre released large quantities
of radioactive particles into the atmosphere, which spread over
much of the western USSR and Europe. The Chernobyl disaster is
widely considered to have been the worst nuclear power plant
accident in history, and is one of only two Level 7 classiﬁed events
on the international nuclear event scale (the other being the Fuku-
shima Daiichi nuclear disaster of 2011).
Of 600 workers present on the site of the accident, 134 received
high doses (0.8–16 Gy) and suffered from radiation sickness. Out of
134 victims, 28 died within 3 months, and another 19 died
between 1987 and 2004 of various causes not necessarily associ-
ated with radiation exposure. In addition, the majority of the
530,000 registered recovery operation workers received doses
between 0.02 Gy and 0.5 Gy between 1986 and 1990 [101]. In April
2013, previously classiﬁed data regarding the Chernobyl accident
were released, demonstrating that three accident victims, with
an estimated exposure dose of 5 Gy, were administered GM-CSF,
(Sandoz Pharma Ltd., Basel, Switzerland) six weeks after the acci-
dent. Following radiation exposures, but prior to treatments with
recombinant drug, the patients exhibited severe granulocytopenia,
with life threatening lung diseases from radiation pneumonitis as
well as infection(s) that were unresponsive to antibiotics, anti-fun-
gal and anti-viral agents. Since no previous use of GM-CSF in
humans had been demonstrated at that time, the authors (Drs. A.
Vorobiov and R.P. Gale of the USSR) injected themselves with
GM-CSF before administering it to the patients. AV had no imme-
diate side effects but reported severe, transient pain in the sacrum,
which required iv morphine [102,103]. RPG’s injection was with-
out any complication. Bone marrow pain is now a well-known side
effect of G-CSF and GM-CSF administrations. Out of the three vic-
tims treated with GM-CSF (treatment schedule not available),
one died of progressive pneumonia (respiratory failure) 2 days
after administration, the other two had hematopoietic recovery
and survived [103]. The authors (recipients of GM-CSF) have not
experienced adverse effects after twenty-seven years of GM-CSF
administration.
7.2. Radiotherapy source accident, Goiânia, Brazil, 1987
The Goiânia accident occurred on 13 September 1987 in the
Brazilian state of Goiás [104,105], after an old radiotherapy
source (137Cs) was stolen from an abandoned hospital site in
the city. The radioactive source was in the form of cesium chlo-
ride salt, which is highly soluble and readily dispersible. Contam-
inations of the environment lead to external radiation exposure
and also internal contamination of several individuals. After the
source capsule ruptured, the remnants of the source assembly
were sold for scrap. One buyer noticed that the source material
glowed blue in the dark making it attractive. Several persons
were fascinated by this and over a period of days friends and rel-
atives came and saw the phenomenon. Fragments of the source
(the size of rice grains) were distributed to several families. This
went on for 5 days and a number of people began showing GI
symptoms arising from their exposure to radiation from the
source. The symptoms were not initially recognized as being
due to radiation exposure. However, one of the exposed persons
took the remnants to the public health department in the city.
This action began a chain of events which led to the discovery
Table 3
List of known radiological accidents where victims received G-CSF and/or GM-CSF treatments.
Year Place Radiation
source
Exposure Exposure
dose
Victims
treated
Treatment details and outcome References
1986 Chernobyl,
Ukraine
40
radionuclides
Acute 5 Gy Three GM-CSF treatment details not available, two exposed victims recovered
and one died
[102,103]
1987 Goiânia,
Brazil
137CS Protracted 2.5–
6.0 Gy
Eight Four victims who received GM-CSF (500 lg/m2/day, iv, dose reduced to
half when neutropenia improved) 5 days before developing neutropenia
and infection survived, other four with infection at the time of GM-CSF
initiation died
[104,105]
1989 San
Salvador, El
Salvador
60Co Acute 3.0–
8.1 Gy
Three GM-CSF (240 lg/m2/day, iv), neutrophil counts improved after 9 or
10 days after treatment initiation, victim with highest dose of exposure
(8 Gy) died, other two with 2.92 and 3.77 Gy exposure doses survived
[106,107]
1990 Soreq,
Israel
60Co Acute 10–20 Gy One GM-CSF (250 lg/m2/day) from day 1 to 18, also IL-3 from day 5–18, blood
cell count improved, given BMT and died on day 36 due to graft vs host
disease
[108]
1992 Nesvizh,
Belarus
60Co Acute 11 Gy One GM-CSF (11.4 lg/kg/day, 1–6 days, 6 lg/kg/day, 16–39 days) and IL-3
(10 lg/kg/day, day 6–31), marrow and blood cell recovered, victim died on
day 108 due to pneumonia and acute respiratory failure
[109]
1996 Gilan, Iran 192Ir Acute 4–5 Gy One G-CSF (400 lg/m2 twice daily, sc, day 22–24, then 300 lg/m2 twice daily
for 10 days), BMT on day 24, recovered
[110]
1998 Istanbul,
Turkey
60Co Acute 0.9–
3.1 Gy
Seven Five victims: 2.2–3.1 Gy, G-CSF (8 lg/kg/day for 11/12 days), Two victims:
0.9–2 Gy, G-CSF (5 lg/kg/day for 11/12 days), Neutrophil and
lymphocytes recovered and all survived
[111]
1999 Henan
Province,
China
60Co Protracted 2.4–
6.1 Gy
Three A. 6.1 Gy, GM-CSF (400 lg/m2/day, 9–32 days, 200 lg/m2/day, 33–
36 days), EPO when hemoglobin was < 90 g/L B. 3.4 Gy, GM-CSF (200 lg/
m2/day, 18–32 days, 50 lg/m2/day, 33–36 days) C. 2.4 Gy, GM-CSF
(400 lg/m2/day, 26–35 days), EPO (120 U/kg/day, day 10–36 days), all
survived
[112]
1999 Tokaimura,
Japan
Gamma (c) +
Neutron (n)
Criticality 1.3–
8.5 Gy c
Three A. 8.5 Gy c, 5.4 Gy n, G-CSF (100 lg/day), EPO, TPO as needed), received
peripheral blood stem cell transplant, died on day 82. B. 4.5 Gy c, 2.9 Gy n,
G-CSF (5 lg/kg 4 days before umbilical cord blood transplant on day 8,
10 lg/kg until day 16), GM-CSF, EPO, TPO, received transplant, died on day
210. C. 1.3 Gy c, 0.8 Gy n, G-CSF (4.5–7.4 lg/kg/day until day 28, survived
[114–116]
0.8–
5.4 Gy n
1999 Yanango,
Peru
192Ir Protracted 80–
143 Gy
One G-CSF (300 lg/day, day 35–42, victim survived [104,117,118]
2000 Prakan,
Thailand
60Co Protracted 1
to > 6 Gy
Nine G-CSF (5–10 lg/kg/day and increased to 20 lg/kg/day) and GM-CSF
(300 lg/day and increased to 500 or 600 lg/day), six survived, three died
on days 38, 47, and 53
[119,120]
2000 Meet Halfa,
Egypt
192Ir Protracted 3.5–4 Gy Five GSF (10 lg/kg/day), all ﬁve survived [121,122]
2005 Nueva,
Aldea, Chile
192Ir Acute 1.3–
1.5 Gy
One G-CSF (10 lg/kg/day, day 6–8 post-radiation exposure), victim survived [123]
2006 Fleurus,
Belgium
60Co Acute 4.2–
4.8 Gy
One Pegylated G-CSF (6 mg/day, initiated on day 28), pegylated EPO and stem
cell factor (on days 32 and 33), victim recovered
[100]
2006 Dakar,
Senegal
192Ir Protracted 3.4 Gy One Pegylated G-CSF (6 mg/day), recombinant SCF (Stemgen), and pegylated
EPO, victim recovered
[100]
2010 Delhi, India 60Co Protracted 2.3–
3.1 Gy
Three G-CSF (5 lg/kg), one with 3.1 Gy exposure died on day 46, other two
survived
[124–127]
It should be noted that published information reporting treatment of Delhi, India accident victims was later retracted by the authors. Limited details are available for all
accidents (additional details for various victims are not available).
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tive contamination, 249 were found to have signiﬁcant levels of
radioactive material in or on their body, 152 people had internal
contamination, 49 individuals required medical treatment, 20 vic-
tims were hospitalized, and of these, 8 had severe bone marrow
impairment. Of the internal contamination victims, 46 were trea-
ted with Radiogardase (Prussian Blue or ferric ferrocyanide) [104].
The International Atomic Energy Agency (IAEA) called it ‘‘one of
the world’s worst radiological incidents’’.
GM-CSF was administered to the 8 victims with severe bone
marrow impairment and initiation of therapy occurred between
24 and 48 days after radiation exposure. The estimated radiation
exposure doses ranged from 2.5 to 6.0 Gy. All 8 individuals who
received rhGM-CSF had neutrophil counts 60.5  109/L prior to
treatment (500 lg/m2/day, iv) until the neutrophil counts
improved to 2  109/L, then the dose was reduced to half for the
next 3 days. Out of 8 treated victims, the 4 who survived, received
GM-CSF within 5 days of developing neutropenia and before the
onset of infectious complications. The other four victims, with
Gram-negative bacterial infections before GM-CSF treatmentswere initiated, succumbed to their injuries. This clinical case study
highlighted several important points: ﬁrst, the rapid rise in granu-
locytes within 12 h of GM-CSF administration; second, the decline
in granulocytes after drug dose attenuation or discontinuation; and
third, the apparent different patterns of recovery in treated and
untreated victims [105].
7.3. San Salvador, El Salvador radiation accident, 1989
A radiological accident occurred on 5th February 1989 at San
Salvador [106,107], El Salvador. A radioactive 60Co source in a
movable source rack became stuck in the irradiation position.
The operator bypassed the safety systems and entered the radia-
tion exposure room with two other workers to free the source rack
manually. The three individuals received high radiation doses and
developed ARS. Their initial hospital treatment in San Salvador and
subsequent, more specialized treatment in Mexico City, were par-
tially effective in countering the acute effects.
Their estimated exposure doses were 3.0–8.1 Gy. On days 24,
26, and 32 after exposure, each victim received rhGM-CSF
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1500/mm3. All three patients responded to GM-CSF and had neu-
trophil counts >1,500/mm3 within 9–20 days of initiating rhGM-
CSF. The feet of two victims had to be amputated. The worker
who had been most exposed (7.9–8.1 Gy) died 197 days after the
exposure; his death was attributed to residual lung damage due
to irradiation [106,107]. The dose estimates for the second and
third victims were 3.77 and 2.92 Gy, respectively. Both of these vic-
tims survived following GM-CSF treatment.
7.4. Irradiator operator accident, Soreq, Israel, 1990
A fatal radiological accident occurred on 21 June 1990
[106,108], at an industrial facility at Soreq, Israel. An operator
entered into the irradiator room and was exposed to an estimated
whole-body dose of 10–20 Gy (60Co) [108]. The accident happened
after the irradiator source rack became stuck in the irradiation
position owing to obstruction by cartons on the internal conveyor.
The operator, having misinterpreted two conﬂicting warning sig-
nals, bypassed installed safety procedures in order to enter the
irradiation room to free the blockage. After a minute or so in the
irradiator room, the operator felt a burning sensation in his eyes
and pounding in his head. He left the room and reported the inci-
dent to a superior. Shortly afterwards he felt sick and started to
retch. He was immediately taken to a hospital where immediate
care was provided. He presented signs and symptoms indicative
of severe hematological and GIS of ARS. Localized skin injury due
to radiation exposure also developed.
The rhGM-CSF treatment was started approximately 9 h after
exposure as a continuous infusion and continued for 18 days at a
dose of 250 lg/m2/day. A BMT was performed on day 4 after expo-
sure. The victim was treated with IL-3 on days 5–18. Growth fac-
tors were discontinued on day 18 due to normalization of white
blood cell counts. The victim died on day 36, probably from graft
vs host disease. Data were thought to indicate that a combination
of rhGM-CSF and IL-3 may lead to early and effective engraftment
and maturation of donor marrow cells [106]. This was the ﬁrst case
in which rhGM-CSF was administered early (about 9 h after radia-
tion exposure).
7.5. Sterilization facility accident, Nesvizh, Belarus, 1992
On 26 October 1991 [109], one victim received an estimated
whole-body exposure of about 11 Gy (with localized area of up
to 20 Gy) from a 60Co source at an industrial sterilization facility.
This victim received GM-CSF (day 1–6 (11.4 lg/kg/day) and day
16–39 (6 lg/kg/day), and IL-3 (day 6–31; 10 lg/kg/day). Neutro-
phil recovery started on day 21, and reticulocytes appeared 10–
12 days later. No platelet recovery occurred. Granulocytes reached
a level of 5  109/L on day 40. The patient died on day 108 from
pneumonia and acute respiratory failure. Hematopoietic recovery
was incomplete but results suggest improvement due to the
growth factor therapy [109].
7.6. The radiological accident, Gilan, Iran 1996
On 24 July 1996 [110], an accident occurred at the Gilan com-
bined-cycle fossil fuel power plant in the Islamic Republic of Iran.
A worker put an unshielded 185 GBq 192Ir source in his pocket for
few h, unaware that the object was an unshielded source used for
industrial radiography [110]. Cytogenetic dosimetry indicated a
whole-body estimated dose exposure of about 4.5 Gy. He was trea-
ted with prophylactic antibiotics and transfused with 7 units of
platelets on day 20 after exposure. Transfusion of platelets on
day 20 produced a transient rise in platelet count, but by day 22
it was clear that further therapy was required, so G-CSF (Leucomax,Schering Plough, Kenilworth, NJ, now known as Merck) treatment
was initiated (400 lg/m2 twice daily, sc) [110]. The victim was
transferred to Paris for possible BMT on day 24. There, platelet
transfusions and antibiotics were continued. G-CSF therapy was
continued at a dose of 300 lg/m2/day for 10 more days until the
white blood cell count showed marked improvement. A marrow
sample taken from the right iliac crest on day 35 showed marrow
with essentially normal appearance, with all cellular elements
present and without abnormal forms. This ﬁnding was surprising
as the previous marrow sample, taken on day 20 from the opposite
iliac crest, was acellular. A skin graft for the chest lesion was per-
formed on day 63. By 15 October 1996 (day 84) he appeared to
have recovered completely, and he was therefore transferred back
to his physician in Tehran on day 95. The intervention with cyto-
kines probably made only a small contribution to the eventual
recovery because treatment was initiated at a stage where bone
marrow recovery was already under way. However, the use of G-
CSF may have accelerated the recovery process.7.7. Teletherapy source accident, Istanbul, Turkey, 1998
A radiological accident occurred when two packages used to
transport 60Co teletherapy sources were sold as scrap metal
[111]. The persons who purchased these packages broke open
the shielded containers, exposing them and several others to radi-
ation in December 1998 and again in January 1999. Eventually a
total of 10 adults showed signs and symptoms of acute radiation
exposure. About 4 weeks after exposure, ﬁlgrastim treatment was
initiated to the seven most severely affected victims and continued
on G-CSF for 6–12 days [111]. The estimated radiation exposure
doses based on dicentric analysis for the 7 most heavily exposed
individuals ranged from 0.9–3.1 Gy; ﬁve of the worst victims were
estimated to have exposures between 2.2 and 3.1 Gy. G-CSF ther-
apy (8 lg/kg/day) was discontinued after 6 days for patients 5–7
(5 lg/kg/day), who were in a less severe condition (exposure dose
0.9–2 Gy), and after 11–12 days of initiation for patients 1–4, who
were in more severe condition.
Five patients with life-threatening thrombocytopenia received
platelet and whole blood transfusions. All victims treated with G-
CSF survived. The ﬁve most severely affected victims left hospital
after 45 days. Although ﬁve victims recovered rapidly after mas-
sive platelet transfusions (24 units), all other patients showed
marked recovery in platelet counts after completion of G-CSF treat-
ment. Such platelet recovery delay has been reported previously,
and this appears to be a negative attribute of G-CSF treatment.7.8. Cobalt source accident, Henan Province, China, 1999
In April 1999 [112], a 60Co source was sold as scrap metal in
China’s Hunan province. The dealer who purchased it, brought
the source to his home, exposing himself, his wife and 8-year-old
son with estimated doses of 2.4, 6.1, and 3.4 Gy, respectively. All
three received GM-CSF treatment when their total white cell count
was below 1  109/L. The scrap metal dealer received 400 lg/m2/
day GM-CSF from day 26–35 and 120 U/kg/day EPO from day 10
to 36. His wife received 400 lg/m2/day GM-CSF from day 9 onward
until day 33 when it was decreased to 200 lg/m2/day and stopped
on day 37. She received testosterone for 7 days to delay menstru-
ation and blood loss, and like her husband, received EPO when
her hemoglobin was <90 g/L. His son received 200 lg/m2/day
GM-CSF starting on day 18 until day 33 when it was decreased
to 50 lg/m2/day, and stopped on day 36 [112]. Gamma globulin,
whole blood, and fresh platelets were provided to each patient.
All patients recovered by day 83 of treatment.
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The Tokaimura nuclear accident occurred on September 30
[113–116], 1999, resulting in two deaths. It was the worst civilian
nuclear radiation accident in Japan prior to the Fukushima Daiichi
nuclear disaster of 2011. The criticality accident occurred in a
uranium reprocessing facility when three workers were preparing
a small batch of fuel for an experimental fast breeder reactor,
using uranium enriched to 18.8%. The precipitation tank reached
critical mass when its ﬁll level, containing about 16 kg of ura-
nium, reached about 40 L. The tank was not designed to hold this
type of solution and was not conﬁgured to prevent criticality
[113].
There were 56 plant workers whose exposures ranged up to
23 mSv and an additional 21 workers received elevated doses
when draining the precipitation tank. Seven workers immediately
outside the plant received doses estimated at 6–15 mSv (combined
neutron and gamma exposure). The three operators’ estimated
doses were: 5.4 Gy of neutrons and 8.5 Gy of gamma for patient
A, 2.9 Gy of neutrons and 4.5 Gy of gamma for patient B, and
0.81 Gy of neutrons and 1.3 Gy of gamma for patient C
[114–116]. The victim having the highest radiation exposure dose,
received peripheral blood stem cell transplantation with identical
human leukocyte antigen. Hematopoietic factors such as G-CSF
(100 lg/day), EPO, TPO and blood components were administered
as needed [116]. The patient developed severe radiation skin
damage, gastrointestinal bleeding, and respiratory failure due to
pulmonary edema and on day 58 he had a cardiopulmonary arrest
and subsequently died on day 82 of multiple organ failure. The
second victim received G-CSF 5 lg/kg/day for 4 days before
umbilical cord blood transplant on day 8 and then 10 lg/kg/day till
day 16). His bone marrow recovered 2 months after the incident.
On day 153 he developed methicillin-resistant Staphylococcus
aureus pneumonia that led to acute respiratory distress syndrome.
He also developed a Cytomegalovirus infection and GI bleeding on
day 145 and died on day 210 due to multiple organ failure. The
third victim was not as close to the source as the two other victims
had been. He was administered G-CSF (4.5–7.4 lg/kg/day) until
day 28. His neutrophils reached a nadir on day 20. His platelets
had decreased slower than the other 2 victims but still necessitated
platelet transfusions on days 17, 20, and 23. He left the hospital on
day 82 and survived [114,115].7.10. Radiography pigtail source accident, Yanango, Peru, 1999
On 20 February 1999 [104,117,118], a radiological accident
occurred when a welder picked up the unshielded 192Ir radiogra-
phy pigtail source and placed it in his pocket. He kept this source
in his pocket for several hours. This resulted in his receiving a high
radiation dose that eventually necessitated the amputation of one
leg. At night he went home and unknowingly exposed his wife and
children to radiation but to a much less extent. At the time of the
accident the source was 37 Ci [117]. According to three different
center measurements, the welder’s estimated doses to the femur
and skin were between 9.966–11.752 Gy and 80–143 Gy, respec-
tively [104,118].
On day 34 the patient’s neutrophils dropped to 1,440/mm3,
and total leucocytes to 1,500/mm3. GM-CSF was initiated on
day 35 at 300 lg/day and continued until day 42, when there
was a signiﬁcant rise in WBCs. G-CSF was administered on day
34 post-exposure until day 42 post-exposure: the patient ulti-
mately survived. It is inconclusive whether his treatment had a
beneﬁcial effect. Though the bone marrow did improve, adminis-
tration was during a time when spontaneous recovery would
have occurred [118].7.11. Teletherapy radiation accident, Samut Prakan, Thailand, 2000
A radiation accident occurred during the January–February
time-frame of 2000 in Thailand’s Samut Prakan province
[119,120]. The accident occurred when an insecurely stored, unli-
censed 60Co radiation source (425 Ci) was recovered by scrap metal
collectors who, together with other workers, dismantled the con-
tainer, unknowingly exposing themselves and others nearby to
ionizing radiation. Over the following weeks, those exposed devel-
oped symptoms of radiation sickness and eventually sought med-
ical attention. Ten victims presented with symptoms of vomiting.
Total-body doses were estimated to range from 1 Gy to > 6 Gy.
Four individuals were found to have received > 6 Gy. Nine victims
who received 2 Gy or more were treated with both G-CSF and
GM-CSF [119,120]. G-CSF administration was started at 250 or
500 lg/day (5–10 lg/kg/day) and in some cases increased to
1,000 lg/day (20 lg/kg/day), if WBCs remained low. GM-CSF
started at 300 lg/day and was increased to 500 or 600 lg/day,
depending on the response of the WBCs. Both G-CSF and GM-CSF
were stopped if the WBC counts improved. Despite these efforts,
victims died on days 38, 47, and 53 post-radiation exposure.
7.12. Radiography source accident, Meet Halfa, Egypt, 2000
On 5 May 2000 [121,122], a resident of Meet Halfa village found
an industrial gamma radiography source (192Ir) that had been lost
earlier. Not knowing that the item was a radioactive source, he
took it to his home and shared it with his wife, sister, 2 sons and
2 daughters. The family believed the source to be a precious metal
and handled it occasionally over the following weeks. On June 5,
the 9-year old younger son died and was found to have marked
bone marrow failure and extensive inﬂammatory skin lesions. On
June 10, a fact-ﬁnding mission from the Ministry of Health found
that 4 other members of the family had similar signs and symp-
toms [121]. On June 16, the father died with bone marrow failure
and extensive skin lesions. On June 25 authorities discovered high
levels of radiation in the family home. By June 28 a source was
found and identiﬁed as 192Ir. The half-life of 192Ir is 74 days. Calcu-
lating the decay process, the source activity would have been
31.5 Ci on the day the source came into the possession of the fam-
ily. The estimated protracted whole-body radiation exposure doses
for father (60 yr) and younger son (9 yr) were 7.5–8 Gy and 5–6 Gy,
respectively (both died) [122]. Doses for the remaining ﬁve family
members were 3.5–4 Gy. The ﬁve remaining family members were
treated with ﬁlgrastim (10 lg/kg/day) and all survived.
7.13. Radiography equipment accident, Nueva Aldea, Chile, 2005
This accident occurred on 14 December 2005 at a cellulose plant
under construction in Nueva Aldea [123], Concepción, Chile. A
radioactive source containing 192Ir fell out of gamma radiograpy
equipment being used at a construction site near 3 workers. At
the time of the accident the activity of the source was 90 Ci.
Worker 1 was determined to have received a total-body dose of
1.3–1.5 Gy, and a dose of up to 1,600 Gy to the surface of his but-
tocks adjacent to a pocket where he had placed the source. Work-
ers 2 and 3 were estimated to have received < 0.5 Gy whole-body
doses [123]. Biodosimetry also was performed from blood samples
on 34 individuals who had worked near the exposed source. One of
these workers was calculated to have received 0.17 Gy and the
remaining 33 workers received < 0.1 Gy.
Only one worker (#1) was admitted to a hospital and treated
with G-CSF (10 lg/kg/day) on 18 December 2005. After collecting
and analyzing hematological and radiological information that
had not been available at the commencement of G-CSF administra-
tion, an IAEA report deemed that G-CSF administration was not
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inhomogeneous character of the exposure. G-CSF administration
was ceased on December 20, 2005 and the patient was given an
experimental treatment with surgical excision followed by two
administrations of mesenchymal stem cells for his local injury.
Within 3 months, the wound on his buttocks had almost healed
completely [123].
7.14. Cobalt source accident, Fleurus, Belgium, 2006
On 11 March 2006 [99], in the city of Fleurus (Belgium), an
alarm went off in a facility used for the sterilization of medical
devices. An operator entered the irradiation room to close the open
cell door. The 60Co sources [activity: 2.96  1016 Bq (800,000 Ci),
dose rate  5,000 Gy h1] were partly out of the security position
at that time. As a consequence, the operator’s whole body was
exposed to this source for about 22 s with a whole-body radiation
dose estimated at 4.2–4.8 Gy with a range to different parts of the
body of 1.5–6.4 Gy. Eighteen days after the incident, the operator
consulted a physician and was diagnosis of accidental radiation
exposure. He was found to have hematological syndrome with a
26% drop in hemoglobin, a platelet nadir of 2,000/mm3, and a leu-
kocyte nadir of 400/mm3. Eight days after hospitalization he devel-
oped septicemia. Treatment with pegylated G-CSF (6 mg/day) was
initiated on day 28 after exposure. On days 32 and 33 post-expo-
sure the victim received pegylated EPO and recombinant human
stem cell factor (SCF). Cytokines had an immediate effect and the
victim had complete resolution of the hematopoietic syndrome
by day 43 [99].
7.15. Iridium radiation device accident, Dakar, Senegal, 2006
In June–August 2006 [99], an industrial radiation device with
192Ir was used but its source did not properly retract into its
shielded container. It was later discovered that the source was
not secured properly. It was estimated that 63 people had received
radiation from the source. The most severely exposed victim was
admitted to a hospital in France on 25 August 2006. He was found
to have a leukocyte nadir of 700/mm3 and a platelet nadir of 8,000/
mm3. Radiation dose reconstruction estimated that the mean dose
was 3.4 Gy, but with a very wide range of doses to speciﬁc parts of
the body; e.g., 1.3 Gy to the liver and up to 75 Gy to the skin of the
left arm. He was diagnosed with hematopoietic syndrome with a
severe cutaneous syndrome. Treatment was initiated with pegylat-
ed G-CSF (6 mg/day), recombinant SCF, and pegylated EPO. The
patient rapidly recovered to normal blood counts but cutaneous
syndrome required additional medical treatments [99].
7.16. Radiation accident, Mayapuri, Delhi, India, 2010
In March 2010 [124–127], the locality of Mayapuri was affected
by a serious radiological accident; an Atomic Energy of Canada
Limited Gammacell 220 research irradiator, owned by Delhi Uni-
versity since 1968 but unused since 1985, was sold at auction to
a scrap metal dealer on 26 February 2010. The orphan source
arrived at a scrap yard in Mayapuri, where it was dismantled on
March 12 by workers unaware of the hazardous nature of the
device. The 60Co source was cut into 11 pieces. The smallest of
the fragments was taken by the owner, who kept it in his wallet;
two fragments were moved to a nearby shop, while the remaining
eight remained in the scrap yard. All of the sources were recovered
by mid-April and transported to the Narora Atomic Power Station,
where it was claimed that all radioactive material originally con-
tained within the device was accounted for. Eight people were hos-
pitalized as a result of radiation exposure, where one died [124].Within a week of incidence, the dealer displayed skin hyper-
pigmentation of the hands and forearm, loss of scalp hair, nausea
and fatigue. With these clinical signs, symptoms and history, he
was diagnosed as a case of suspected radiation injury. This patient
received repeated transfusions of platelets and packed red blood
cells, ﬂuids, and treated with antibiotics and a systemic antifungal
agent. He also was treated with G-CSF (5 lg/kg). His exposure dose
as calculated during the course of treatment was 3.1 Gy. He did not
respond to the treatment and died on 26 April 2010, within
6 weeks of exposure. It is important to note that his treatment
started 5 weeks after exposure (19 April) [124]. Seven other per-
sons working in the shop during that period also were traced. Of
those traced, ﬁve individuals developed skin manifestations and
fatigue. Based on blood biomarkers, the deceased victim and the
additional four exposed individuals demonstrated signs of acute
radiation exposure [125]. Two exposed victims were treated with
G-CSF and they survived. Unfortunately, the publication containing
the details of the treatment of this accident victims [126] was
retracted by the authors [127].
There have been a number of radiation incidents since 1986
(Hanoi, Vietnam, 1992; Tomsk, Russia, 1993; Tammiku, Estonia,
1994; San Jose, Costa Rica, 1996; Lilo, Georgia, 1997; Sarov, Russia,
1997; Panama, 2000; Cochabamba, Bolivia, 2002; Shandong Jining,
China, 2004; London, UK, 2006; Turmero, Venezuela, 2010; Fuku-
shima, Japan, 2011) where CSFs were not used because victims
either did not have signiﬁcant myelosuppression or for other rea-
sons [23].8. Summary and conclusion
The published results with G-CSF and GM-CSF using various
animal models of hematopoietic ARS suggest consistent radiopro-
tective efﬁcacy for survival and blood leukocyte recovery across
species. The efﬁcacy is dependent on the dose of CSF [73], treat-
ment schedule [67,75], duration of the treatment [68,82,84], ani-
mal strains/source [73] and radiation dose [68,75], but largely
independent of the radiation source. There are signiﬁcant short-
comings in some studies in relation to design (small sample size
for canines, minipigs, and NHPs), lack of concurrent controls in
some studies, insufﬁcient information regarding supportive care,
euthanasia criteria, inadequate animal pharmacokinetics data for
human dose conversion [82], difﬁculty in verifying data accuracy/
integrity/adequacy (non-good laboratory practice studies), and
interpretation. These experimental deﬁciencies tend to limit the
usefulness of some studies presented above. However, despite of
some of the limitations of the published works, the aggregate
results of these publications support the concept that rhG-CSF
treatments provide a signiﬁcant hematopoietic recovery and, in
turn, survival for individuals with ARS.
Treating radiation injuries is a complicated process. In the
majority of radiation accidents, radiation exposure is un-uniform,
resulting in a sparing of portions of the bone marrow. Therefore,
stimulating the victim’s own spared hematopoietic elements with
the use of CSF is a promising strategy. The general conclusion by
several investigators and clinicians is that CSF improves blood leu-
kocyte levels and for some victims this may prove to be life-saving.
Others suggest however, that G-CSF and GM-CSF treatments may
adversely affect blood platelet counts so the IAEA recommends
that platelet counts be monitored when G-CSF is being adminis-
tered [110]. Further, it needs to be noted that G-CSF, alone or in
combination with other cytokines or chemotherapeutic agents,
has been shown to increase cell cycle entry by murine and human
hematopoietic stem cells, a state that reduces their repopulating
efﬁciency following transplantation [128]. This may be relevant
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patients that also receive BMT.
Among radiation incident victims from 1986 to the present,
more than 51 individuals have been treated with recombinant CSFs
following accidental radiation exposures. Results from various
treatments are hard to interpret. The number of victims who
received CSF was small for each accident and CSF treatment usually
started late after radiation exposure; in many cases the accident
victims did not know they had been exposed to high doses of radi-
ation until days after exposure. In general, the use of CSF appeared
to be beneﬁcial, and would have been more effective if adminis-
tered earlier after radiation exposure. Results for the efﬁcacy of
CSF with radiation-induced myelosuppression are positive, but
not conclusive, by any means. Recent studies with large animal
models (NHP) clearly demonstrate the radioprotective efﬁcacy of
rhG-CSF treatments as well as capability of these recombinants
to promote for hematopoietic recovery. Such experimental demon-
strations strongly suggest their usefulness to radiation-exposed
victims. The US FDA may approve G-CSF and GM-CSF for the man-
agement of radiation-induced aplasia in near future.Declaration of Interest
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